Relmada Therapeutics (RLMD) Tops Q2 EPS by 10c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• TD Cowen Resumes Keyera Corp. (KEY:CN) (KEYUF) at Buy
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings